USPTO serial 75557320
MERISTEM THERAPEUTICS
Reviewed by CopyMark Law Group
Reg. 2499316Status 710
- Filing date
- Status date
- Registration date
- Oct 23, 2001
- Examiner
- RUPP, BRIAN
- Law office
- —
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with MERISTEM THERAPEUTICS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
63170 Aubiere, FR
63170 Aubiere, FR
63170 Aubiere, FR
F-63000 CLERMONT-FERRAND, FR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John A. Clifford
JOHN A. CLIFFORD MERCHANT & GOULD P.C.PO BOX 2910MINNEAPOLIS, MN 55402-0910UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | [ Chemicals for use in the manufacture of photographic materials, namely, dyes, wetting agents, fixing agents, developing agents, and stabilizers; chemicals for use in the manufacture of paints, dyes, cosmetics, glues and surfactants; chemicals for use in the manufacture of horticultural materials, namely, soil conditioners, fertilizers; chemicals for use in the manufacture of hormones, peptides, enzymes, and proteins, namely, plant and animal and microbial growth hormones, growth regulators and inhibitors, diagnostic regents, cell growth media, cell regulatory agents, amino acids, DNA fragments, RNA fragments, DNA probes, RNA probes, genetic cloning materials, genetic expression amplifiers ] | SECTION 8 - CANCELLED | — |
| 003 | [ Proteins for use as ingredients in skin lotions, oils and creams; for use as ingredients in sun tan lotions, oils and creams; for use as ingredients in skin hydrating lotions, oils and creams, namely, collagen, serum albumin, RNA, DNA and their extracts, amino acids, ribosomes, ceramides, immunostimulating or immunoregulatory hormones, all obtained from plants; and enzymes for use as ingredients in skin lotions, oils and creams; for use as ingredients in sun tan lotions, oils and creams; for use as ingredients in skin hydrating lotions, oils and creams, namely, proteases, hydrolases, lipases, deshydroxylases and celluloses, all obtained from plants ] | SECTION 8 - CANCELLED | — |
| 005 | [ Pharmaceutical preparations for use in the treatment of cystic fibrosis, obesity, emphysema, hemoglobin insufficiency, blood oxygen insufficiency, albumin insufficiency, collagen insufficiency, auto-immune diseases, namely human immunodeficiency virus and multiple sclerosis, iron insufficiency and rabies; veterinary preparations for the treatment of rabies, obesity, auto-immune diseases, namely, feline immunodeficiency virus and simian immunodeficiency virus, in livestock, domestic pets and wild animals, namely foxes and rodents; acaricides, algaecides, biopesticides, herbicides, insecticides, miticides, pesticides and weed killers for agricultural, domestic or commercial use; pharmaceutical preparations produced from plants or containing proteins produced from plants, for use in the treatment of cystic fibrosis, obesity, emphysema, hemoglobin insufficiency, blood oxygen insufficiency, albumin insufficiency, collagen insufficiency, auto-immune diseases, namely, human immunodeficiency virus and multiple sclerosis, iron insufficiency and rabies; therapeutic proteins, hormones, peptides and their complexes, derivatives and cofactors, namely, human serum albumin, lactoferrin, hemoglobin, collagen and procollagen for use in the treatment of cystic fibrosis, obesity, emphysema, hemoglobin insufficiency, blood oxygen insufficiency, albumin insufficiency, collagen insufficiency, auto-immune diseases, namely human immunodeficiency virus and multiple sclerosis, iron insufficiency and rabies; vaccines including antibodies or glycoproteins, namely, glycoprotein G, lipases, namely, gastric lipase, pancreatic lipase; and medicines and pharmaceutical preparations obtained from genetically modified plants or containing the extracts of genetically modified plants for use in the treatment of cystic fibrosis, obesity, emphysema, hemoglobin insufficiency, blood oxygen insufficiency, albumin insufficiency, collagen insufficiency, auto-immune diseases, namely human immunodeficiency virus and multiple sclerosis, iron insufficiency and rabies ] | SECTION 8 - CANCELLED | — |
| 042 | Scientific and industrial research, namely, biotechnology research on chemical products intended for industry, science, photography, agriculture, horticulture, forestry, on pharmaceutical or cosmetic proteins obtained from plants, on pharmaceutical products, veterinary products, hygiene products within the pharmaceutical field, on dietary products for children, on biotechnology products obtained from plants; biological and biotechnological services, namely, genetic modification of plants and plant cells, embryos, cals, seeds, pollen leaves, stems and cuttings, biological and biochemical analysis of genetically modified plants, plant cells, embryos, cals, seeds, pollen, leaves, stems and cuttings, in-vitro reproduction and regeneration of genetically modified plants, plant cells, embryos, cals, seeds, pollen, leaves, stems and cuttings, field and greenhouse reproduction of genetically modified plants, plant cells, embryos, cals, seeds, pollen, leaves, stems and cuttings, and field trials of genetically modified plants; expression of therapeutic, cosmetic or nutritional proteins or protein fragments through genetic modification, regeneration, and reproduction of plants, plant cells, embryos, cals, seeds, pollen, leaves, stems and cuttings; biotechnology laboratories; engineering work and research and development in plant biotechnology | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by BIOCEM
- Other trademarks owned by BIOCEM
- Other trademarks owned by BIOCEM
- Other trademarks owned by MERISTEM THERAPEUTICS
- Other trademarks in Class 001
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named MERISTEM THERAPEUTICS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 25, 2012 | CAEX | CANCELLED SEC. 8 (10-YR)/EXPIRED SECTION 9 | — |
| May 12, 2008 | C15P | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| May 6, 2008 | PLGL | ASSIGNED TO PARALEGAL | — |
| Apr 23, 2008 | 815F | REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED | — |
| Apr 23, 2008 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Apr 23, 2008 | ASGN | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | — |
| Jan 18, 2007 | CFIT | CASE FILE IN TICRS | — |
| Oct 23, 2001 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jul 31, 2001 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jul 18, 2001 | NPUB | NOTICE OF PUBLICATION | — |
| Feb 14, 2001 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 22, 2000 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 31, 2000 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 15, 1999 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 11, 1999 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 21, 1999 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 13, 1999 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Apr 29, 1999 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 23, 1999 | DOCK | ASSIGNED TO EXAMINER | — |